Allurion Technologies (ALUR) Jefferies 2024 Global Healthcare Conference summary

Company evolution and product innovation

• Developed a procedureless, swallowable balloon for weight loss, paired with a proprietary digital behavior change program.

• Over 150,000 patients treated since 2016, with best-in-class weight loss and maintenance results.

• The balloon is covered by 50+ patents and is delivered in a 15-minute office visit, emptying and passing naturally after four months.

• Patients lose over 15% of total body weight in four months, maintaining 96% of that loss after one year.

Competitive landscape and GLP-1 impact

• GLP-1 drugs were a headwind in late 2023 but are now seen as a long-term tailwind due to high patient churn.

• 25% of new patients have previously tried prescription weight loss drugs.

• The balloon delivers similar weight loss to GLP-1s but faster and with better long-term maintenance.

Clinical progress and regulatory milestones

• The AUDACITY FDA pivotal trial completed enrollment in fall 2023, two months ahead of schedule.

• Patients in the trial are eligible for up to two balloon cycles, potentially achieving over 20% weight loss.

• Data readout expected by end of 2024, with subsequent FDA submission planned.